The Cooper Companies, Inc.

Equities

COO

US2166485019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
94.33 USD +4.54% Intraday chart for The Cooper Companies, Inc. -0.59% -0.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Adjusts Price Target on Cooper Companies to $107 From $105 MT
Baird Adjusts Price Target on Cooper Companies to $118 From $116 MT
Transcript : The Cooper Companies, Inc., Q2 2024 Earnings Call, May 30, 2024
Cooper Fiscal Q2 Non-GAAP EPS, Net Sales Rise; Full Year Outlook Raised, Shares Advance MT
The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024 CI
Cooper Companies Guides For FY 2024 EPS of $3.54-$3.60 on Revenue of $3.86-$3.91 Billion, vs CIQ Analyst Consensus of $3.55/Share on Revenue of $3.88 Billion MT
Earnings Flash (COO) COOPERCOMPANIES Posts Q2 Revenue $942.6M MT
Citigroup Raises Price Target on Cooper Companies to $116 From $108, Keeps Buy Rating MT
Cooper Companies Insider Sold Shares Worth $5,521,230, According to a Recent SEC Filing MT
North American Morning Briefing : Markets on Hold -2- DJ
All eyes on the Fed Our Logo
ANALYST RECOMMENDATIONS : 3M Company, Snowflake, Splunk, Micron, Nvidia... Our Logo
Redburn Atlantic Upgrades Cooper Companies to Buy From Neutral, Adjusts Price Target to $125 From $93.75 MT
Not a care in the world Our Logo
JPMorgan Upgrades Cooper Companies to Overweight From Neutral, Adjusts Price Target to $120 From $100 MT
ANALYST RECOMMENDATIONS : Broadcom, Tesla, Walmart, Entain, Virgin Money UK Our Logo
Cooper Companies Insider Sold Shares Worth $24,659,342, According to a Recent SEC Filing MT
Piper Sandler Adjusts Price Target on Cooper to $115 From $110, Maintains Overweight Rating MT
Cooper to Benefit From Strong Contacts Market as Demand Continues, Morgan Stanley Says MT
Mizuho Adjusts Price Target on Cooper to $115 From $102.50, Maintains Buy Rating MT
Morgan Stanley Lifts Price Target on Cooper Cos. to $95 From $88.75 After Better-Than-Expected Fiscal Q1; Equalweight Kept MT
Cooper Companies lifts annual revenue forecast on strong contact lens demand RE
Transcript : The Cooper Companies, Inc., Q1 2024 Earnings Call, Feb 29, 2024
Cooper Fiscal Q1 Non-GAAP EPS, Net Sales Increase; Issues Outlook MT
The Cooper Companies, Inc. Raises its Revenue Guidance for the Fiscal Year 2024 CI
Chart The Cooper Companies, Inc.
More charts
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys, Biofinity toric & Biofinity XR toric, Biofinity multifocal, Biofinity toric multifocal, clariti 1 day, clariti 1 day toric, clariti 1 day multifocal, MiSight 1 day, Avaira Vitality and Avaira Vitality toric. CooperSurgical is a fertility and women’s health company dedicated to assisting women, babies and families around the world. CooperSurgical provides a range of products and services with an emphasis on improving fertility solutions, empowering office-based care, and advancing hospital care within women’s health. CooperSurgical’s brands include Paragard, ER-Complete, Fetal Pillow, INSORB, PGT-Complete, RUMI II and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
94.31 USD
Average target price
108.2 USD
Spread / Average Target
+14.68%
Consensus
  1. Stock Market
  2. Equities
  3. COO Stock
  4. News The Cooper Companies, Inc.
  5. Citigroup Raises Price Target on Cooper Companies to $116 From $108, Keeps Buy Rating